| abstract |
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology, immunology and virology. Described is an expression vector for producing an immunobiological agent for inducing an immune response against the SARS-CoV-2 virus, based on human adenovirus serotype 26 and having a sequence SEQ ID NO: 1, or SEQ ID NO: 2, or SEQ ID NO: 3. Also disclosed is an expression vector based on human adenovirus serotype 5 and having the sequence SEQ ID NO: 4, or SEQ ID NO: 5, or SEQ ID NO: 6, and an expression vector based on human adenovirus serotype 5 and having the sequence SEQ ID NO: 7, or SEQ ID NO: 8, or SEQ ID NO: 9. Also disclosed is an immunobiological agent containing the declared expression vectors, use of this agent for inducing an immune response against SARS-CoV-2 virus. Also described is a method of inducing an immune response involving sequential or simultaneous administration of the versions of the immunobiological agent in an effective amount.EFFECT: group of inventions provides creating a safe immunobiological agent inducing a specific immune response against the SARS-CoV-2 coronavirus.7 cl, 4 dwg, 6 tbl, 21 ex |